Table 2 Top 20 gene ontology (GO) terms of differentially expressed genes between CotG-p40 treated cells and control cells
GO ID | GO Description | Corrected p valuea | Cluster frequencyb | Total frequencyc |
|---|---|---|---|---|
48,513 | organ development | 9.04E-03 | 27/107 (10.0%) | 1792/17785 (10.0%) |
48,731 | system development | 9.04E-03 | 32/107 (29.9%) | 2422/17785 (13.6%) |
42,471 | ear morphogenesis | 1.97E-02 | 5/107 (4.6%) | 66/17785 (0.3%) |
34,754 | cellular hormone metabolic process | 1.97E-02 | 5/107 (4.6%) | 66/17785 (0.3%) |
9913 | epidermal cell differentiation | 1.97E-02 | 5/107 (4.6%) | 66/17785 (0.3%) |
48,856 | anatomical structure development | 1.97E-02 | 32/107 (29.9%) | 2656/17785 (14.9%) |
8285 | negative regulation of cell proliferation | 2.26E-02 | 10/107 (9.3%) | 379/17785 (2.1%) |
90,068 | positive regulation of cell cycle process | 2.26E-02 | 4/107 (3.7%) | 43/17785 (0.2%) |
42,573 | retinoic acid metabolic process | 2.26E-02 | 3/107 (2.8%) | 17/17785 (0.0%) |
9888 | tissue development | 2.26E-02 | 14/107 (13.0%) | 750/17785 (4.2%) |
30,728 | ovulation | 2.26E-02 | 3/107 (2.8%) | 18/17785 (0.1%) |
48,598 | embryonic morphogenesis | 2.26E-02 | 9/107 (8.4%) | 336/17785 (1.8%) |
60,429 | epithelium development | 2.26E-02 | 9/107 (8.4%) | 337/17785 (1.8%) |
48,562 | embryonic organ morphogenesis | 2.26E-02 | 6/107 (5.6%) | 140/17785 (0.7%) |
7166 | cell surface receptor linked signaling pathway | 2.26E-02 | 19/107 (17.7%) | 1280/17785 (7.1%) |
42,904 | 9-cis-retinoic acid biosynthetic process | 2.26E-02 | 2/107 (1.8%) | 4/17785 (0.0%) |
42,905 | 9-cis-retinoic acid metabolic process | 2.26E-02 | 2/107 (1.8%) | 4/17785 (0.0%) |
35,238 | vitamin A biosynthetic process | 2.26E-02 | 2/107 (1.8%) | 4/17785 (0.0%) |
7275 | multicellular organismal development | 2.26E-02 | 33/107 (30.8%) | 2971/17785 (16.7%) |
6692 | prostanoid metabolic process | 2.41E-02 | 3/107 (2.8%) | 21/17785 (0.1%) |